In this episode of Talking Techniques, supported by Bio-Rad, we discuss a key component of many gene therapies: recombinant adeno-associated viruses (rAAVs) and their production. These viruses act as efficient, accurate delivery vesicles for the gene therapy’s plasmid.Speaking to Associate Director of Biopharma Product Marketing at Bio-Rad Laboratories, Mark White, we take a look at the different expression systems used for their production and compare their advantages, before looking at some of the challenges involved in the production rAAVs, such as host-cell contamination.Discover the tools that can help minimize host-cell contamination and differentiate between nuclease resistant and nuclease reactive contaminant DNA and find out about some of the most exciting developments in rAAV technologies. Contents:The role of rAAVs in gene therapies: 00:40-02:15The production of rAAVs and gene therapies: 02:15-03:30Why are HEK cells so popular for cell therapy production? 03:30-05:45HEK vs SF9 Insect cell expression systems: 05:45-06:45Challenges in cell therapy expression systems: 06:45-08:05Host DNA contamination: 08:05-10:30The risks of host DNA contamination: 10:30-12:45Key techniques to minimize host DNA contamination: 12:45-14:40The advantages of ddPCR in gene therapy production: 14:40-17:50Distinguishing between nuclease resistant and nuclease reactive host cell DNA: 17:50-19:10The most exciting developments in rAAV technology: 19:10-20:20What is one thing you would ask for to improve rAAV and gene therapy development 20:20-26:38 Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.